A multi-Centre, Exploratory Trial to Assess the Mechanisms of Molecular Activity, Safety and Tolerability of One Dose Level of FE 999301 by Intravenous Infusions in Patients with Active Inflammatory Bowel Disease (IBD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Mar 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olamkicept (Primary)
Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
Focus Pharmacodynamics; Pharmacogenomic
Acronyms FUTURE; Future-010

Most Recent Events

02 Mar 2021 Results published in the Gastroenterology
16 Jul 2018 Status changed from recruiting to completed.
13 Sep 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight